LYEL
Lyell Immunopharma, Inc.Healthcare · $241M market cap
Verdict
We can't put a fair value on LYEL right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow LYEL
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 10, 2026: no open-market purchases, 1 sale worth $6K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter
Sales
Other filings
About Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works